CA
NZ
UK
AU
IND
US
Zura Bio shares rose 3.1% to $4.17 today. The gain comes after a difficult stretch, with the stock down 29% over the past month. Looking further back, the picture is stronger. The stock remains up 99% over one year, which means it had nearly …
The OTC line rose 13.1% to $21.49. The week, month and three-month returns all show the same 11.6%, a pattern that usually signals a stale or one-print OTC quote rather than a genuine U.S. catalyst. No GlobeNewswire or SEC item dated today was found. …
Valneva's OTC line rose 12.3% to $3.37. The Nasdaq-listed ADS also traded higher. No same-day company release was located. The stock is up 29% over three months, but down 28% over one year and 78% over five years. Without a new trial or contract …
Device companies usually trade on steadier drivers than clinical-stage biotech names.Revenuegrowth, regulatory clearances and hospital adoption tend to matter more than single trial readouts. That makes guidance and commercial updates especially important when judging whether a rally has staying power.
Context matters here. Five-year losses of 80% or more are common among these names, which shows how far sentiment has fallen. Against that backdrop, even a strong single-day gain moves the stock only a small distance from its lows.
Sofwave shares jumped 34.0% to $13.94 today. The rally follows the company's 24 September disclosure that China's National Medical Products Administration (NMPA) approved its system for mid-to-lower facial wrinkles. The approval was backed by a 200-patient randomised controlled trial in China, where 95.1% of …
● Wang Erqi's beneficial ownership fell from 6.77% to 3.35% after Jin Medical issued 79,762,048 new Class A shares.
● Silexion Therapeutics received aNasdaqbid-price deficiency notice for closing below $1.00 for 30 consecutiveBusinessdays.
● SANUWAVE Health received aNasdaqdeficiency notice after itsMarket Valueof Listed Securities stayed below $50 million for 30 days.
● SOBR Safe now qualifies as a shell company after discontinuingRevenueoperations and cutting its workforce.
Please wait processing your request...